CN111686226A - Traditional Chinese medicine composition for treating colon cancer and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating colon cancer and preparation method and application thereof Download PDFInfo
- Publication number
- CN111686226A CN111686226A CN202010680553.1A CN202010680553A CN111686226A CN 111686226 A CN111686226 A CN 111686226A CN 202010680553 A CN202010680553 A CN 202010680553A CN 111686226 A CN111686226 A CN 111686226A
- Authority
- CN
- China
- Prior art keywords
- colon cancer
- traditional chinese
- chinese medicine
- treating colon
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 87
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 68
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000009636 Huang Qi Substances 0.000 claims abstract description 18
- 241000132012 Atractylodes Species 0.000 claims abstract description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 13
- 241001106477 Paeoniaceae Species 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000036039 immunity Effects 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 37
- 206010028980 Neoplasm Diseases 0.000 abstract description 27
- 230000004083 survival effect Effects 0.000 abstract description 22
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 16
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000002035 prolonged effect Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 230000004580 weight loss Effects 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 240000009138 Curcuma zedoaria Species 0.000 description 4
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 4
- 235000006533 astragalus Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000045403 Astragalus propinquus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 240000009022 Smilax rotundifolia Species 0.000 description 3
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000027503 bloody stool Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000893536 Epimedium Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 2
- 235000018905 epimedium Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019509 white turmeric Nutrition 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000893531 Epimedium koreanum Species 0.000 description 1
- 241001660849 Epimedium pubescens Species 0.000 description 1
- 241001362411 Epimedium sagittatum Species 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 235000015912 Impatiens biflora Nutrition 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000206469 Pulsatilla Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 244000020191 Salix babylonica Species 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 240000004274 Sarcandra glabra Species 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating colon cancer, which comprises the following active ingredients in parts by weight: 2-4 parts of radix astragali, 0.5-1 part of herba epimedii, 1-1.5 parts of red paeony root, 0.5-1 part of rhizoma zedoariae, 1.5-3 parts of rhizoma smilacis glabrae and 0.5-1.5 parts of fried bighead atractylodes rhizome. The invention also provides a preparation method and application of the traditional Chinese medicine composition for treating colon cancer. Experiments of colon cancer tumor-bearing mice show that when the traditional Chinese medicine composition for treating colon cancer is combined with chemotherapeutic drugs for application, although the tumor inhibition effect of the chemotherapeutic drugs is not obviously enhanced, the traditional Chinese medicine composition can obviously prolong the survival time of the mice, relieve the weight loss caused by the chemotherapeutic drugs and improve the T lymphocytes of the miceLevel, in particular significantly increased CD4+T lymphocytes, CD8+The T lymphocyte level shows that the traditional Chinese medicine composition for treating colon cancer can improve the body immunity of a colon cancer patient, so that the life quality of the patient is improved, and the survival time is prolonged.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating colon cancer, and a preparation method and application thereof.
Background
Colon cancer is a malignant tumor of the digestive system, and is characterized by abdominal pain, diarrhea, mucopurulent bloody stool, stool deformation, alternate occurrence of diarrhea and constipation, bloody stool or purulent bloody stool and the like. At present, operation and chemotherapy are mainly used as main means for clinically treating colon cancer, but the chemotherapy often causes the immune system of a human body to be disordered, and the life quality of a patient is reduced.
In the prior art, a patent with publication number CN110575485A discloses a traditional Chinese medicine composition for treating colon cancer and a preparation method thereof, which takes sophora japonica branch, weeping willow branch, ground beetle, stone-like omphalia, rosin, mica powder, Chinese pulsatilla root, garden balsam stem, gecko, areca seed, dandelion, mulberry root, sesame oil and glabrous sarcandra herb as raw materials; the evaluation on the effect of the traditional Chinese medicine composition in the patent shows that the traditional Chinese medicine composition has a good treatment effect on colon cancer.
Patent publication No. CN105535716A discloses an oral Chinese medicine for treating rectal cancer and colon cancer, which takes rhizoma Smilacis Bockii, herba Potentillae Discoloris, herba et Gemma Agrimoniae, folium Iridis Tectori, rhizoma Curculiginis, semen Cuscutae, fructus Psoraleae, parched Atractylodis rhizoma, parched radix Paeoniae alba, radix Codonopsis, radix astragali, Scorpio, and Scolopendra as raw materials, and has effects of warming and invigorating kidney yang, invigorating spleen, removing toxic substance, promoting blood circulation, and resolving hard mass. The patent medicine can effectively inhibit the growth of cancer and has obvious effect of reducing cancer and tumor mass.
Patent publication No. CN105797003A discloses a probiotic fermented traditional Chinese medicine compound composition for treating colon cancer, which comprises radix Scutellariae, radix rehmanniae, radix Sophorae Flavescentis, radix scrophulariae, herba Patriniae, herba Hedyotidis Diffusae, cortex moutan, fructus Aurantii, herba cistanches, herba Solani Lyrati, radix Panacis Quinquefolii, fructus crataegi preparata, caulis Sargentodoxae and semen Coicis; mouse experiments prove that the composition can effectively inhibit the growth of solid tumors of colon cancer and improve the activity of the composition in inhibiting colon adenocarcinoma SW1116 solid tumors.
The three traditional Chinese medicine formulas have a certain treatment effect on colon cancer, but all start from the aspect of inhibiting cancer, mainly aim at solid tumors and pay no attention to survival time and life quality; for tumor patients, prolonging the survival time and improving the life quality are the final treatment aims. Particularly, in chemotherapy patients, the clinical treatment idea is to inhibit solid tumors by using chemotherapy drugs and improve the immunity of the patient body by using traditional Chinese medicines, thereby achieving the purposes of prolonging the survival time and improving the life quality. Obviously, the above patents do not meet this need in chemotherapy patients and do not fundamentally improve the quality of life and survival of colon cancer patients. Therefore, it is necessary to provide a drug for treating colon cancer to improve the life quality and prolong the survival time of patients, starting from improving the autoimmunity of the patients.
Disclosure of Invention
According to one aspect of the invention, the invention provides a traditional Chinese medicine composition for treating colon cancer, which comprises the following raw material medicines as main active ingredients in parts by weight: 2-4 parts of radix astragali, 0.5-1 part of herba epimedii, 1-1.5 parts of red paeony root, 0.5-1 part of rhizoma zedoariae, 1.5-3 parts of rhizoma smilacis glabrae and 0.5-1.5 parts of fried bighead atractylodes rhizome.
The therapeutic rule of the traditional Chinese medicine composition for treating colon cancer of the invention is as follows:
the inventor discovers that the cause of the colon cancer is 'deficiency of both spleen and kidney' as the basis and 'damp-stasis mutual accumulation' as the standard, and the 'damp' is mainly used and 'stasis' is used as the assistant in the standard. Therefore, it is indicated for tonifying spleen and kidney, clearing damp and resolving stasis.
The traditional Chinese medicine composition for treating colon cancer disclosed by the invention mainly uses radix astragali which is sweet and slightly warm in taste, and has the effects of tonifying spleen and qi, and the herba epimedii is capable of tonifying kidney yang, and the two medicines are combined to tonify spleen and kidney and tonify the innate and acquired basis, and are monarch medicines together; the fried bighead atractylodes rhizome, which is used for tonifying qi and strengthening the spleen, is combined with the glabrous greenbrier rhizome, is used for tonifying the spleen and eliminating dampness and is used as a ministerial drug together to strengthen the effect of the astragalus on tonifying the middle-jiao and qi; radix Paeoniae Rubra and Curcumae rhizoma are used as adjuvant and guiding drugs for promoting blood circulation and removing blood stasis. The medicines are compatible, so that the effects of tonifying spleen and kidney, eliminating dampness and removing blood stasis are achieved, the functions of internal organs of a human body are recovered, healthy qi is sufficient, the disease resistance of the human body is enhanced, namely, the immunity is improved, and the effects of strengthening healthy qi and eliminating pathogenic factors are achieved.
Specifically, the method comprises the following steps:
and (3) radix astragali: namely, dried roots of Astragalus membranaceus (Fisch.) Bge, Astragalus membranaceus (Astragalus membranaceus) Bge. Sweet and warm. It enters lung and spleen meridians. Invigorating qi, invigorating yang, promoting fluid production, nourishing blood, activating stagnancy, relieving arthralgia, expelling toxin, and expelling pus.
Herba Epimedii: the herba Epimedii is dried leaf of Epimedium brevicomum Maxim, Epimedium sagittatum Maxim, Epimedium pubescens Maxim or Epimedium koreanum Nakai. Pungent, sweet and warm. It enters liver and kidney meridians. Tonify kidney yang, strengthen tendons and bones, dispel wind-damp. Pharmacological experimental research shows that epimedium can increase blood flow of heart and cerebral vessels, promote hemopoiesis, immunity and bone metabolism, and has the functions of resisting senility, resisting tumor, etc.
Red peony root: is dried root of Paeonia lactiflora Pall or Paeonia veitchii Lynch of Ranunculaceae. Bitter and slightly cold. It enters liver meridian. Clear heat and cool blood, dissipate blood stasis and alleviate pain. After stir-baked, the property of the drug is moderate, activating blood and alleviating pain without hurting the middle energizer.
Zedoary turmeric: is dried rhizome of Curcuma zedoaria Phaeocaulis Val, Curcuma zedoaria Curcaakwangsiensis S.G.LeeetC.F.Liang or Curcuma wenyujin Y.H.Chen et C.Ling. Pungent, bitter and warm. It enters liver and spleen meridians. Move qi and break blood, resolve food stagnation and alleviate pain.
Glabrous greenbrier rhizome: is dried rhizome of Smilax glabra Roxb. Sweet, bland and mild. It enters liver and stomach meridians. Remove toxicity, remove dampness, and smooth joints.
White atractylodes rhizome: is dried rhizome of Atractylodes macrocephala Koidz of Compositae. Bitter, sweet and warm. It enters spleen and stomach meridians. To invigorate the spleen, replenish qi, dry dampness and induce diuresis.
In some embodiments, the main active ingredients of the traditional Chinese medicine composition for treating colon cancer comprise the following raw material medicines in parts by weight: 3 parts of radix astragali, 1 part of herba epimedii, 1.5 parts of red paeony root, 1 part of rhizoma zedoariae, 2 parts of rhizoma smilacis glabrae and 1.5 parts of fried bighead atractylodes rhizome.
In some embodiments, the traditional Chinese medicine composition for treating colon cancer of the present invention may further comprise a pharmaceutically acceptable carrier or excipient.
In some embodiments, the Chinese medicinal composition for treating colon cancer may be decoction, oral liquid, granule, powder, tablet, capsule.
According to another aspect of the present invention, a preparation method of the above traditional Chinese medicine composition for treating colon cancer is provided, wherein when the traditional Chinese medicine composition for treating colon cancer is a decoction or an oral liquid, the preparation method comprises the following steps:
mixing the raw materials according to a ratio, soaking in water for 20-40min, decocting for 0.5-1 h, and filtering.
In some embodiments, the ratio of the bulk drug to water is 1: 10-15.
In some embodiments, when the Chinese medicinal composition for treating colon cancer is decoction or oral liquid, the preparation method thereof may further include the following steps:
decocting the raw materials, filtering to obtain filtrate and filter residue, repeatedly decocting the filter residue for 1-2 times, mixing the filtrates obtained by each decoction, sterilizing, and cooling to room temperature to obtain the traditional Chinese medicine.
According to still another aspect of the invention, the application of the traditional Chinese medicine composition for treating colon cancer in preparing a medicine for improving the immunity of the organism is provided.
In some embodiments, the application of the traditional Chinese medicine composition for treating colon cancer in preparing a medicine for treating colon cancer is provided. Specifically, the composition can be used in combination with surgery and chemotherapy to treat colon cancer.
When the traditional Chinese medicine composition for treating colon cancer is decoction or oral liquid, one dose is about 300 mL. One dosage is the filtrate obtained by decocting the raw materials of the traditional Chinese medicine composition for treating colon cancer (such as 30g of radix astragali, 10g of herba epimedii, 15g of radix paeoniae rubra, 10g of rhizoma zedoariae, 20g of rhizoma smilacis glabrae and 15g of fried rhizoma atractylodis macrocephalae) with water according to the dosage of one time. After the traditional Chinese medicine decoction is prepared according to the existing traditional Chinese medicine decoction preparation method, the traditional Chinese medicine decoction can be concentrated according to actual needs to obtain the traditional Chinese medicine oral liquid.
The Chinese medicinal composition for treating colon cancer is prepared from raw materials of radix astragali, herba epimedii, red paeony root, zedoary, glabrous greenbrier rhizome and fried largehead atractylodes rhizome in a compatible manner. Experiments of colon cancer tumor-bearing mice show that when the traditional Chinese medicine composition for treating colon cancer is combined with chemotherapeutic drugs for application, although the tumor inhibition effect of the chemotherapeutic drugs is not obviously enhanced, the traditional Chinese medicine composition can obviously prolong the survival time of the mice, relieve the weight loss caused by the chemotherapeutic drugs, improve the T lymphocyte level of the mice, and especially obviously improve CD4+T lymphocytes, CD8+The T lymphocyte level shows that the traditional Chinese medicine composition for treating colon cancer can improve the body immunity of a colon cancer patient, so that the life quality of the patient is improved, and the survival time is prolonged.
Drawings
FIG. 1 is a graph showing the trend of tumor volume changes during the administration of the drugs to the groups of mice in the experimental part of the present invention;
FIG. 2 is a graph showing the tumor weights at the time of sacrifice in each group of mice in the experimental part of the present invention;
FIG. 3 is a graph showing the trend of body weight change during administration to groups of mice in the experimental part of the present invention;
FIGS. 4-5 are graphs showing survival curves for groups of mice in the experimental part of the present invention;
FIG. 6 shows the peripheral blood CD4 at the time of death of each group of mice in the experimental part of the present invention+T lymphocyte expression profile;
figure 7 is the bookExperimental part of the invention mice in each group were sacrificed peripheral blood CD8+T lymphocyte expression profile.
Detailed Description
The present invention will be described in further detail with reference to the following detailed description and the accompanying drawings.
The traditional Chinese medicine composition for treating colon cancer comprises the components and the weight of the components in the embodiments 1-6.
Example 1
A traditional Chinese medicine composition for treating colon cancer comprises the following main active ingredients: 30g of radix astragali, 10g of herba epimedii, 15g of red paeony root, 10g of rhizoma zedoariae, 20g of rhizoma smilacis glabrae and 15g of fried bighead atractylodes rhizome.
The components are taken, and the traditional Chinese medicine decoction is prepared according to the existing traditional Chinese medicine decoction preparation method, wherein the proportion is one dose, and one dose is about 300 mL.
The preparation method of the traditional Chinese medicine decoction comprises the following steps: mixing radix astragali, herba Epimedii, radix Paeoniae Rubra, Curcumae rhizoma, rhizoma Smilacis Glabrae, and parched Atractylodis rhizoma according to weight parts to obtain mixture, soaking in water at a material-to-liquid ratio of 1:10 for 0.5 hr, decocting for 0.5 hr, filtering to obtain first filtrate, decocting the residue for 1 time, mixing the filtrate with the first filtrate, sterilizing, cooling to room temperature, and packaging.
Example 2
A traditional Chinese medicine composition for treating colon cancer comprises the following main active ingredients: 30g of radix astragali, 10g of herba epimedii, 10g of red paeony root, 10g of rhizoma zedoariae, 30g of rhizoma smilacis glabrae and 10g of fried bighead atractylodes rhizome.
The components are taken, and the traditional Chinese medicine oral liquid is prepared according to the existing traditional Chinese medicine oral liquid preparation method, wherein the proportion is one dose, and one dose is about 300 mL.
The preparation method of the traditional Chinese medicine oral liquid comprises the following steps: mixing radix astragali, herba Epimedii, radix Paeoniae Rubra, Curcumae rhizoma, rhizoma Smilacis Glabrae, and parched Atractylodis rhizoma according to weight parts to obtain mixture, soaking in water at a material-to-liquid ratio of 1:15 for 20min, decocting for 1h, filtering to obtain first filtrate, decocting the residue for 1 time, mixing the filtrate with the first filtrate, sterilizing, cooling to room temperature, and packaging.
Example 3
A traditional Chinese medicine composition for treating colon cancer comprises the following main active ingredients: 20g of radix astragali, 10g of herba epimedii, 10g of red paeony root, 5g of rhizoma zedoariae, 30g of rhizoma smilacis glabrae and 15g of fried bighead atractylodes rhizome.
Mixing the above materials, adding carrier or excipient, and making into granule according to the existing preparation method of Chinese medicinal granule.
The granular medicine can be prepared by the following existing method:
obtaining filtrate according to the method for preparing decoction in the embodiment 1, concentrating the filtrate under reduced pressure to obtain clear paste, adding maltodextrin into the clear paste, and then carrying out spray drying to obtain dry paste powder; then adding maltodextrin into the dry paste powder to obtain mixed powder; then adding 90% ethanol-water solution into the mixed powder to prepare soft material, and sieving the soft material to obtain wet granules; and finally, drying the wet granules to obtain the finished product.
The granules are divided into 10g each for convenient clinical use and administration.
Example 4
A traditional Chinese medicine composition for treating colon cancer comprises the following main active ingredients: 30g of radix astragali, 10g of herba epimedii, 10g of red paeony root, 5g of rhizoma zedoariae, 20g of rhizoma smilacis glabrae and 10g of fried bighead atractylodes rhizome.
Mixing the above materials with suitable vehicle or excipient, pulverizing, mixing, and making into powder.
Example 5
A traditional Chinese medicine composition for treating colon cancer comprises the following main active ingredients: 40g of radix astragali, 10g of herba epimedii, 15g of red paeony root, 10g of rhizoma zedoariae, 30g of rhizoma smilacis glabrae and 15g of fried bighead atractylodes rhizome.
Taking the components, wet granules can be prepared according to the method of the embodiment 3, and then the wet granules are tableted and dried to obtain the tablet medicine.
Example 6
A traditional Chinese medicine composition for treating colon cancer comprises the following main active ingredients: 20g of radix astragali, 5g of herba epimedii, 15g of red paeony root, 10g of rhizoma zedoariae, 30g of rhizoma smilacis glabrae and 15g of fried bighead atractylodes rhizome.
Mixing the above materials with suitable vehicle or excipient, pulverizing, mixing, making into dry powder, grading, and making into capsule.
In order to verify the treatment effect of the traditional Chinese medicine composition for treating colon cancer, decoction is prepared according to the proportion of the raw material medicines given in the example 1, and the following tests are carried out after concentration and the treatment effect is evaluated. Unless otherwise specified, the reagents and cells used below were all commercially available.
First, animal experiment
1. Test method
The murine intestinal cancer cell line CT26 is inoculated under the skin of a BALB/C mouse to construct a colon cancer tumor-bearing mouse model, and the model is divided into 4 groups after successful modeling: control group, low dose group (0.65g crude drug/ml), medium dose group (1.30g crude drug/ml), and high dose group (2.60g crude drug/ml). Oxaliplatin was administered 5mg/kg (0.2mL) intraperitoneally per group 3 times per week for a total of 7 times. The Chinese medicinal materials (low dose group, high dose group, and middle dose group) are administered by intragastric administration with 0.2mL of Chinese medicinal liquid with corresponding concentration, and the control group is administered by intragastric administration with 0.2mL of water 1 time per day. The activity, weight, tumor volume and survival rate of the mice are monitored and recorded, the mice are sacrificed when the mice are in an dying state, transplanted tumors are separated and weighed, the metastasis conditions of the lung and the liver are observed, and the level of peripheral blood T lymphocytes is detected by a flow cytometer.
2. Results of the experiment
A total of 23 mice were successfully modeled 8 days after the breeding of the tumors, and were randomly divided into 4 groups of 6 mice each (5 mice in the low dose group).
The trend of tumor volume change in each group of mice during the administration is shown in FIG. 1, and the tumor weight of each group of mice at the time of sacrifice is shown in FIG. 2. As can be seen from FIGS. 1-2, there was no significant difference in tumor volume in the mice of each group during the administration period and tumor weight in the mice of each group after the administration period, wherein the tumor weight of the mice of the control group tended to decrease, probably due to the short survival time of the mice of the control group and the short tumor formation time when the tumors were weighed. No liver and lung metastasis was observed in any group of mice.
The body weight change trend of each group of mice during the administration period is shown in fig. 3. As can be seen from fig. 3, the body weight of the mice in the middle dose group was significantly increased (P ═ 0.042) compared with the control group during the administration period, and the mobility of the mice was also significantly improved compared with the control group.
After the administration, the survival rates of the mice in the high dose, medium dose, low dose groups and the control group are recorded in table 1, and the survival curves of the mice in each group are shown in fig. 4 to 5. As can be seen from table 1, the overall survival rate of the traditional Chinese medicine group (i.e., the low dose group, the high dose group, and the medium dose group) is 70.59%, which is more than twice as high as the survival rate of the control group. As can be seen from fig. 4, the survival time of each traditional Chinese medicine group (high dose, medium dose, low dose) mouse is prolonged compared with the control group; as can be seen from fig. 5, the survival time of the mice in the low dose group and the medium dose group was significantly prolonged compared to the control group (P ═ 0.0418).
TABLE 1 comparison table of survival rates of mice in traditional Chinese medicine and control group
| Experimental group | Total number (only) | Death number (only) | Survival rate |
| |
6 | 2 | 66.67％ |
| |
6 | 1 | 83.33％ |
| |
5 | 2 | 60 |
| Control group | |||
| 6 | 4 | 33.33％ |
Peripheral blood CD4 at necroscopy time for each group of mice+T lymphocyte expression is shown in FIG. 6, peripheral blood CD8+T lymphocyte expression is shown in FIG. 7. As can be seen from FIGS. 6-7, the peripheral blood CD4 of the middle-dose group mice+T lymphocyte (P ═ 0.024) and peripheral blood CD8 of medium and low dose group mice+T lymphocytes (P ═ 0.029) were all significantly elevated compared to the control group.
Experiments of colon cancer tumor-bearing mice show that when the traditional Chinese medicine composition for treating colon cancer is combined with chemotherapeutic drugs for application, although the tumor inhibition effect of the chemotherapeutic drugs is not obviously enhanced, the traditional Chinese medicine composition can obviously prolong the survival time of the mice, relieve the weight loss caused by the chemotherapeutic drugs, improve the T lymphocyte level of the mice, and especially obviously improve CD4+T lymphocytes, CD8+The T lymphocyte level shows that the traditional Chinese medicine composition for treating colon cancer can improve the body immunity of a colon cancer patient, so that the life quality of the patient is improved, and the survival time is prolonged.
Claims (9)
1. The traditional Chinese medicine composition for treating colon cancer is characterized by comprising the following main active ingredients in parts by weight: 2-4 parts of radix astragali, 0.5-1 part of herba epimedii, 1-1.5 parts of red paeony root, 0.5-1 part of rhizoma zedoariae, 1.5-3 parts of rhizoma smilacis glabrae and 0.5-1.5 parts of fried bighead atractylodes rhizome.
2. The traditional Chinese medicine composition for treating colon cancer according to claim 1, which is characterized in that the main active ingredients comprise the following raw material medicines in parts by weight: 3 parts of radix astragali, 1 part of herba epimedii, 1.5 parts of red paeony root, 1 part of rhizoma zedoariae, 2 parts of rhizoma smilacis glabrae and 1.5 parts of fried bighead atractylodes rhizome.
3. The traditional Chinese medicine composition for treating colon cancer according to claim 1 or 2, wherein the traditional Chinese medicine composition for treating colon cancer further comprises a medically acceptable carrier or excipient.
4. The traditional Chinese medicine composition for treating colon cancer according to claim 1 or 2, wherein the traditional Chinese medicine composition for treating colon cancer is decoction, oral liquid, granules, powder, tablets and capsules.
5. The preparation method of the traditional Chinese medicine composition for treating colon cancer according to claim 4, wherein the traditional Chinese medicine composition for treating colon cancer is decoction or oral liquid, and the preparation method comprises the following steps:
mixing the raw materials according to a ratio, soaking in water for 20-40min, decocting for 0.5-1 h, and filtering.
6. The preparation method of the traditional Chinese medicine composition for treating colon cancer, as claimed in claim 5, is characterized in that the material-to-liquid ratio of the raw material medicine to water is 1: 10-15.
7. The method for preparing a Chinese medicinal composition for treating colon cancer as claimed in claim 6, wherein, when the Chinese medicinal composition for treating colon cancer is decoction or oral liquid, the preparation method further comprises the following steps:
decocting the raw materials, filtering to obtain filtrate and filter residue, repeatedly decocting the filter residue for 1-2 times, mixing the filtrates obtained by each decoction, sterilizing, and cooling to room temperature to obtain the traditional Chinese medicine.
8. The use of the Chinese medicinal composition for treating colon cancer according to any one of claims 1 to 4 in the preparation of a medicament for improving immunity of the organism.
9. The use of the Chinese medicinal composition for treating colon cancer according to any one of claims 1 to 4 in the preparation of a medicament for treating colon cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010680553.1A CN111686226B (en) | 2020-07-15 | 2020-07-15 | Traditional Chinese medicine composition for treating colon cancer and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010680553.1A CN111686226B (en) | 2020-07-15 | 2020-07-15 | Traditional Chinese medicine composition for treating colon cancer and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111686226A true CN111686226A (en) | 2020-09-22 |
| CN111686226B CN111686226B (en) | 2021-11-02 |
Family
ID=72485967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010680553.1A Active CN111686226B (en) | 2020-07-15 | 2020-07-15 | Traditional Chinese medicine composition for treating colon cancer and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111686226B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300592A (en) * | 2022-06-30 | 2022-11-08 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Traditional Chinese medicine composition for preventing postoperative recurrence and metastasis of intestinal cancer and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101543570A (en) * | 2008-03-24 | 2009-09-30 | 北京凯瑞创新医药科技有限公司 | Smilax glabra total aglycone oral pharmaceutical preparation as well as preparation method and application thereof |
| CN103432520A (en) * | 2013-04-06 | 2013-12-11 | 耿平 | Oral traditional Chinese medicine formula for treating cancer hypercoagulability |
| CN110664960A (en) * | 2018-12-29 | 2020-01-10 | 南京中山制药有限公司 | Traditional Chinese medicine composition for gastric mucosa precancerous lesion and preparation method and application thereof |
-
2020
- 2020-07-15 CN CN202010680553.1A patent/CN111686226B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101543570A (en) * | 2008-03-24 | 2009-09-30 | 北京凯瑞创新医药科技有限公司 | Smilax glabra total aglycone oral pharmaceutical preparation as well as preparation method and application thereof |
| CN103432520A (en) * | 2013-04-06 | 2013-12-11 | 耿平 | Oral traditional Chinese medicine formula for treating cancer hypercoagulability |
| CN110664960A (en) * | 2018-12-29 | 2020-01-10 | 南京中山制药有限公司 | Traditional Chinese medicine composition for gastric mucosa precancerous lesion and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 李佳，等: "中医药防治大肠癌复发转移的研究概况", 《中医杂志》 * |
| 詹丹丹，等: "张海波针药并用治疗肠癌经验", 《中医药导报》 * |
| 阙华发，等: "乳宁Ò号对乳腺癌MA-891细胞株生长转移的影响", 《上海中医药大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300592A (en) * | 2022-06-30 | 2022-11-08 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Traditional Chinese medicine composition for preventing postoperative recurrence and metastasis of intestinal cancer and application thereof |
| CN115300592B (en) * | 2022-06-30 | 2023-09-26 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Traditional Chinese medicine composition for preventing postoperative recurrence and metastasis of intestinal cancer and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111686226B (en) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1326554C (en) | Antitumour medicine | |
| CN102000175B (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN101485803B (en) | Chinese medicinal composition for treating menoxenia and dysmenorrhea | |
| CN109999164A (en) | There is the Chinese materia medica preparation of nourishing qi and blood, strengthening vital QI to eliminate pathogenic factors effect for lung cancer therapy | |
| CN111686226B (en) | Traditional Chinese medicine composition for treating colon cancer and preparation method and application thereof | |
| CN105996024A (en) | Nourishing nutrient combination for soup cooking and preparation method of combination | |
| CN1049827C (en) | Anti-cancer powder | |
| CN106421432A (en) | Traditional Chinese medicine for treating aged body deficiency syndrome and delaying senescence | |
| CN102552537B (en) | Chinese medicinal composition for treating qi and blood loss | |
| CN101954022B (en) | Chinese medicinal composition for treating lung cancer | |
| CN102204978B (en) | Medicinal composition for treating cancer pain and preparation thereof | |
| CN105816813A (en) | Medicine composition for treating breast cancer and preparing method and application of medicine composition | |
| CN1079252C (en) | Compound graceful jassamine preparation | |
| CN104398975A (en) | Traditional Chinese medicinal preparation for treating fibroadenoma of breast and preparation method thereof | |
| CN104001100A (en) | Traditional Chinese medicine composition for treating PICC (Peripherally Inserted Central Catheter) phlebothrombosis and preparation method of traditional Chinese medicine composition | |
| CN102614432B (en) | Traditional Chinese medicine composition for treating cervicitis | |
| CN111388564B (en) | Traditional Chinese medicine for treating bradyarrhythmia | |
| CN102166303B (en) | Chinese medicinal composition for treating chronic atrophic gastritis | |
| CN108524731B (en) | Traditional Chinese medicine composition for treating myasthenia gravis and preparation thereof | |
| CN101485823A (en) | Medicament for treating lung cancer and preparation method thereof | |
| CN105362933A (en) | Application of artemisia argyi-containing pharmaceutical composition in preparation of drug for treatment of amenorrhoea | |
| CN104721738A (en) | Traditional Chinese medicine preparation for treating nipple discharge and preparation method thereof | |
| CN111617227A (en) | Traditional Chinese medicine for treating pestilence qi infection | |
| CN113368211A (en) | Traditional Chinese veterinary medicine composition for treating tumors of dogs and cats and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |